ReviewPharmacoEconomics - open2023

Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Rachel Houten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.